What Dolgenal Treats: Main Uses and Benefits

Dolgenal is commonly used to help with symptoms related to physical discomfort and chronic, debilitating nerve pain. It is relevant for easing symptoms related to heightened physiological activity, such as burning or shooting discomfort in conditions like diabetic neuropathy and postherpetic neuralgia (pain after shingles). The active ingredient, Pregabalin, is utilized across domains where additional symptomatic support is needed, including neuropathic pain, Generalized Anxiety Disorder (GAD), and partial seizures.

It is applied across domains where additional symptomatic support is needed, including the chronic aches and tenderness characteristic of fibromyalgia, and it may assist with symptom clusters that may become intense or disruptive, such as emotional tension and restlessness in GAD. This supportive use helps patients cope more steadily with these persistent, disruptive symptoms. The goal of this therapeutic application is to provide support that helps ease the overall symptom burden and assists with maintaining functional stability.

Quick Fact:	Supportive Management for Symptoms that Interfere with Functioning
Primary Focus	Symptoms that create noticeable physiological strain
Key Benefit	Contributes to improved day-to-day comfort during periods of heightened symptoms
Relevant Conditions	Conditions presenting with systemic or localized discomfort

This application provides supportive relief when symptoms interfere with routine activities, which supports general well-being during symptomatic phases.

Eligibility Map: Who Can and Cannot Use Dolgenal — Official Regulatory Information

---

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Adults (18 years and older) are eligible for all approved uses. Pediatric patients aged 1 month and older are eligible only for the adjunctive treatment of partial-onset seizures.
Populations for whom use is not recommended (if applicable)	Pregnant women (unless benefit clearly outweighs risk) and breastfeeding women are not recommended to use Dolgenal. Use is not established for non-seizure indications in children and adolescents (under 18 years).
Populations for whom use is contraindicated	Patients with a known hypersensitivity to Pregabalin or any of the excipients are contraindicated. Use is also prohibited for individuals with rare hereditary metabolic disorders such as galactose intolerance.
Age-related eligibility rules	Older adults (over 65) may require dose modification due to potential decline in kidney function. Safety and efficacy have not been established for most indications in the pediatric population.
Condition-specific eligibility rules	Patients with reduced renal function (kidney impairment) must have their dose adjusted based on the degree of clearance, as the medicine is eliminated almost exclusively by the kidneys. Hepatic impairment does not typically require a dose adjustment.
Pregnancy and lactation eligibility status (if explicitly documented)	Pregnancy: Use should not be used; effective contraception is required for women of childbearing potential. Lactation: Not recommended during treatment.
Eligibility-related restrictions	Caution and monitoring are required for patients with a history of substance abuse and for those with compromised respiratory function or pre-existing cardiovascular compromise.

---

Eligibility Classifications (High-Level)

Classification	Official Regulatory Wording (Examples)
Eligibility severity classification (as defined in official documents)	Contraindicated, Not recommended, Use not established, Dose reduction required.
Regulatory basis (EMA / FDA / etc.)	Summary of Product Characteristics (SmPC) / Prescribing Information (PI).
Eligibility-context constraints (as defined in official documents)	Restriction based on renal clearance status, age/indication mismatch, or hypersensitivity to the active ingredient.

---

Resulting Eligibility Structure

Official Eligibility Statements:

• Adults (18+), are eligible for all approved uses, but those with reduced renal function must have their dose adjusted.
• Use is contraindicated in patients with a history of hypersensitivity to Pregabalin or excipient-related hereditary metabolic disorders.
• Safety and efficacy have not been established for children and adolescents (under 18) for most indications, though it is approved for partial-onset seizures in patients aged 1 month and older.
• The medicine should not be used during pregnancy, and women of childbearing potential must use effective contraception.

Connection to the overall eligibility profile (2–4 sentences): The regulatory documents define the eligible population as primarily adults, with strict non-eligibility established by absolute contraindications related to hypersensitivity and certain metabolic disorders. For eligible individuals, use is further restricted by mandatory conditions related to physiological status, specifically requiring dose modification if renal function is impaired. Final constraints include age-based restrictions on established safety and prohibition or strong recommendation against use during pregnancy and lactation.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Dolgenal (Pregabalin) primarily around pharmacodynamic augmentation and specific pharmacokinetic non-interactions.

Pharmacodynamic Interactions

Co-administration with Central Nervous System (CNS) depressants, including substances such as alcohol (ethanol), Oxycodone, or Lorazepam, results in additive CNS depression. This interaction is documented to increase the official risk of somnolence and dizziness.

Regulatory labeling also notes that combining Pregabalin with ACE Inhibitors may result in an increased risk of angioedema, and co-administration with Thiazolidinediones is associated with additive effects on peripheral edema and weight gain.

Pharmacokinetic Profile and Restrictions

Pregabalin is officially documented to not inhibit or induce major human CYP450 enzymes; therefore, it is not expected to cause clinically relevant pharmacokinetic interactions with medicines like Carbamazepine or Lamotrigine. The regulatory profile notes that Cimetidine increases the plasma concentration of Pregabalin due to an inhibition of renal clearance.

For the Extended-Release formulation, the official label specifies a timing constraint requiring that the medicine must be taken after the evening meal and not on an empty stomach to ensure the intended exposure is achieved. Due to its primary elimination via the kidneys, patients with renal impairment will experience increased plasma exposure of the medicine.

Enzyme Inhibition and Molecular Targeting

Dolgenal's primary action involves inhibiting the Cyclooxygenase (COX) enzymes, specifically both COX-1 and COX-2. This mechanism acts at the molecular level to block the initial step in a critical biochemical cascade.

---

Suppression of Eicosanoid Mediators

By blocking the COX enzymes, the drug prevents the conversion of arachidonic acid into prostaglandins and other eicosanoid signaling molecules. This suppression of key chemical mediators decreases the level of specific signaling molecules and is central to the drug's resulting physiological changes.

---

Resulting Physiological Modulation

The decreased availability of prostaglandins leads to two main physiological outcomes: a generalized reduction of peripheral nerve sensitization and a diminished local circulatory response (vasodilation). This targeted molecular inhibition results in a systemic physiological change, leading to the modulation of thermal regulation and afferent nerve activity.

Dolgenal is administered exclusively via the oral route and is available in hard capsules, an oral solution, and extended-release (ER) tablets. The official usage protocol mandates a precise dosing and timing schedule tailored to the formulation. Immediate-release (IR) capsules and solutions are taken in two or three divided doses daily, which is essential for maintaining steady levels, and they may be consumed with or without food. In contrast, the ER tablets are taken only once daily and must be administered after an evening meal to ensure the specific timed release of the drug.

Therapy is initiated at a low total daily dose, typically 150 mg, and is then gradually increased, or titrated, over multiple weeks in increments—usually after a one-week interval—until the required maintenance dose is achieved. Labeled maximum daily doses vary by formulation and condition, ranging up to 600 mg for IR forms. It is a mandatory administration constraint that the ER tablets must be swallowed whole and must not be crushed, split, or chewed, as this alters the drug's sustained-release mechanism.

A key procedural instruction is the required dose reduction for patients with reduced kidney function (renal impairment), as the drug is eliminated primarily unchanged by the kidneys. This reduction is based on creatinine clearance. For pediatric patients being treated for partial seizures, dosing is determined by body weight. Finally, when discontinuing treatment, the dose must always be gradually tapered over a minimum of one week.

---

Official Administration Constraints

Constraint	Detail
Route	Oral administration only.
IR Frequency	Two or three times per day.
ER Frequency	Once daily, after an evening meal.
Renal Adjustment	Mandatory dose reduction based on kidney function.
Discontinuation	Required tapering over a minimum of one week.

Research Evidence / Overview of Studies

Phase 3 Clinical Trials

Research explored the drug's role in studies focusing on mild-to-moderate forms of the condition. Two Phase 3 studies reported on symptom severity over a 12-week period.

One study used a primary endpoint to measure changes in a standardized pain scale. The data included information comparing the drug to a competitor regarding changes in pain levels.

---

Dosage and Administration Studies

One study evaluated taking the drug with food versus without food in relation to absorption levels.

Another study reported on the timeframe of observed changes in symptom relief following dosing.

---

Combination Therapy Research

Research examined the combination's effect on both pain and inflammation in patient-reported outcomes. This research was conducted over a six-month period.

---

Safety Profile

Long-term safety was examined in a study that included various patient groups. The research collected data on adverse events.

Further research continues to explore the drug’s profile compared to other treatments.

Key Studies & References

1. Integrated Analysis of Phase 3 Randomized Controlled Trials of Ketorolac Tromethamine in Moderate-to-Severe Acute Pain Management
2. Ketorolac - StatPearls [Internet]: Clinical Pharmacology and Indications
3. Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review (Relevant to Long-term Safety)

Common questions about Dolgenal (FAQ)

Q: What is Dolgenal used for?

Dolgenal is a medication used to treat mild to moderate pain and to reduce fever.

Q: How should I take Dolgenal?

The correct way to take Dolgenal is determined by your healthcare provider and is usually based on your weight, age, and the severity of your condition. It's important to follow the instructions on the product label or those given to you by your doctor or pharmacist. Generally, the medication is taken by mouth with a glass of water. Do not exceed the recommended dose.

Q: Can children take Dolgenal?

Yes, Dolgenal can be used in children, but it's crucial to use the correct formulation and dose for the child's age and weight. Always consult a pediatrician or pharmacist before giving this medication to a child and use a product specifically made for children, such as a liquid or chewable form, to ensure accurate dosing.

Q: What are the possible side effects of Dolgenal?

Like all medicines, Dolgenal can cause side effects, although not everybody gets them. Common side effects are usually mild and may include:

• Upset stomach or nausea
• Headache

Serious side effects are rare but require immediate medical attention. These may include signs of a severe allergic reaction (such as rash, itching, severe dizziness, or trouble breathing) or signs of liver problems (such as yellowing of the skin or eyes).

Q: Is it safe to take Dolgenal with other medicines?

Taking Dolgenal with certain other medicines can increase the risk of side effects. It is essential to inform your healthcare provider or pharmacist about all other prescription and non-prescription drugs, vitamins, and herbal supplements you are currently taking to check for potential drug interactions.

Q: What should I do if I miss a dose?

If you miss a dose of Dolgenal, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.

How to Store and Dispose of Dolgenal?

Dolgenal (Pregabalin) requires adherence to specific regulatory requirements for storage and handling to ensure product stability.

Official Storage Conditions

Requirement	Details
Temperature	Store at controlled room temperature, between 20°C and 25°C (68°F and 77°F). Brief excursions up to 30°C are permitted.
Environment	Avoid excessive heat and moisture; the product should be kept in a dry place.
Packaging	Must be stored in its original container or package.
Child Safety	The medication must be kept strictly out of the reach and sight of children and pets.

Disposal Instructions

Unused or expired Dolgenal must be safely thrown away according to local guidelines. The official guidance states that the medicine should not be disposed of via household wastewater (flushing) or typical household trash.